Hanna Salm, Markus K Schuler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Luise Mütze, Karin Arndt, Christine Hofbauer, Klaus-Dieter Schaser, Jürgen Weitz, Jochen Schmitt, Martin Eichler
{"title":"肉瘤患者治疗决策的偏好。患病率及相关因素——来自PROSa研究的结果。","authors":"Hanna Salm, Markus K Schuler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Luise Mütze, Karin Arndt, Christine Hofbauer, Klaus-Dieter Schaser, Jürgen Weitz, Jochen Schmitt, Martin Eichler","doi":"10.1159/000543456","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. The objective of this analysis was to identify factors that are associated with sarcoma patients wanting to take a more active or passive role.</p><p><strong>Methods: </strong>Data was obtained as part of a nationwide multicenter study (PROSa) aiming to investigate the structure and quality of medical care of sarcoma patients in Germany and their determinants. The study was conducted between 2017 and 2020 in 39 study centers. For the present analysis, cross-sectional data of adult patients with sarcoma of any entity were analyzed. Control preference was measured with the control preference scale (CPS). Preferences were divided in patient-led, shared, or physician-led-decision-making. Associated factors were analyzed exploratively using multivariable multinominal logistic regression models. We included socio-economical and medical variables with stepwise backward variable selection.</p><p><strong>Results: </strong>We included 1081 patients (48.6% female). 402 patients (37.2%) preferred to be in control about treatment decisions, while 400 patients (37.0%) favored shared responsibility. 25.8% (n = 279) wished to rather leave the control to the treating physician. Older patients were more likely to prefer shared decision-making than younger patients aged 18 to 40 years (age group: > 75 years: Odds Ratio (OR) .53, 95% confidence interval (95% CI) .28; .99). Patients with a metastatic tumor desired shared decision making compared to those without metastases (metastasis: OR 1.61, 95% CI 1.09; 2.38). When comparing the patients who preferred physician-led decision making with those who favored to be in control, older patients also preferred leaving the control to the physician and were less inclined to make the decisions by themselves: (18 to > 40 years vs > 75 years: OR .28, 95% CI .15; .55). With secondary school (8/9 years) as reference, patients holding a high school degree were more likely to prefer patient-led decision-making over physician-led decision making (OR 2.00, 95% CI 1.26; 3.09). Patients with sarcoma of the abdomen/retroperitoneum were more predisposed to taking control in treatment decisions compared to those with sarcoma of the back/spine or lower limb (back/spine: OR .18, 95% CI .06; .54, lower limb: OR .56, 95% CI .37; .85). With an income of 1250 €/month as reference, patients with a higher income were more likely to take control (> 2750€/month: OR 1.7, 95% CI 1.0; 3.1).</p><p><strong>Conclusion: </strong>The findings of our study demonstrate that patients with metastatic disease are more likely to seek a joint decision, while those of higher age and lower education level are less likely to actively participate in treatment decisions. The results suggest that the impact of advanced illness may influence preferences to participate.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-21"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors - Results from the PROSa Study.\",\"authors\":\"Hanna Salm, Markus K Schuler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Luise Mütze, Karin Arndt, Christine Hofbauer, Klaus-Dieter Schaser, Jürgen Weitz, Jochen Schmitt, Martin Eichler\",\"doi\":\"10.1159/000543456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. The objective of this analysis was to identify factors that are associated with sarcoma patients wanting to take a more active or passive role.</p><p><strong>Methods: </strong>Data was obtained as part of a nationwide multicenter study (PROSa) aiming to investigate the structure and quality of medical care of sarcoma patients in Germany and their determinants. The study was conducted between 2017 and 2020 in 39 study centers. For the present analysis, cross-sectional data of adult patients with sarcoma of any entity were analyzed. Control preference was measured with the control preference scale (CPS). Preferences were divided in patient-led, shared, or physician-led-decision-making. Associated factors were analyzed exploratively using multivariable multinominal logistic regression models. We included socio-economical and medical variables with stepwise backward variable selection.</p><p><strong>Results: </strong>We included 1081 patients (48.6% female). 402 patients (37.2%) preferred to be in control about treatment decisions, while 400 patients (37.0%) favored shared responsibility. 25.8% (n = 279) wished to rather leave the control to the treating physician. Older patients were more likely to prefer shared decision-making than younger patients aged 18 to 40 years (age group: > 75 years: Odds Ratio (OR) .53, 95% confidence interval (95% CI) .28; .99). Patients with a metastatic tumor desired shared decision making compared to those without metastases (metastasis: OR 1.61, 95% CI 1.09; 2.38). When comparing the patients who preferred physician-led decision making with those who favored to be in control, older patients also preferred leaving the control to the physician and were less inclined to make the decisions by themselves: (18 to > 40 years vs > 75 years: OR .28, 95% CI .15; .55). With secondary school (8/9 years) as reference, patients holding a high school degree were more likely to prefer patient-led decision-making over physician-led decision making (OR 2.00, 95% CI 1.26; 3.09). Patients with sarcoma of the abdomen/retroperitoneum were more predisposed to taking control in treatment decisions compared to those with sarcoma of the back/spine or lower limb (back/spine: OR .18, 95% CI .06; .54, lower limb: OR .56, 95% CI .37; .85). With an income of 1250 €/month as reference, patients with a higher income were more likely to take control (> 2750€/month: OR 1.7, 95% CI 1.0; 3.1).</p><p><strong>Conclusion: </strong>The findings of our study demonstrate that patients with metastatic disease are more likely to seek a joint decision, while those of higher age and lower education level are less likely to actively participate in treatment decisions. The results suggest that the impact of advanced illness may influence preferences to participate.</p>\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\" \",\"pages\":\"1-21\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000543456\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543456","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
被诊断患有威胁生命的疾病的影响可能会影响参与治疗决策的偏好。该分析的目的是确定与肉瘤患者希望采取更积极或被动角色相关的因素。方法:数据是作为一项全国性多中心研究(PROSa)的一部分获得的,旨在调查德国肉瘤患者的医疗保健结构和质量及其决定因素。该研究于2017年至2020年在39个研究中心进行。在本分析中,我们分析了任何实体的成年肉瘤患者的横断面数据。采用控制偏好量表(CPS)测量控制偏好。偏好分为患者主导、共同决策和医生主导决策。采用多变量多项式logistic回归模型对相关因素进行探索性分析。我们采用逐步后向变量选择纳入社会经济和医学变量。结果:纳入1081例患者(女性48.6%)。402名患者(37.2%)倾向于控制治疗决策,而400名患者(37.0%)倾向于分担责任。25.8% (n = 279)的患者希望将对照组交给主治医生。老年患者比18 - 40岁的年轻患者更倾向于共同决策(年龄组别:55 - 75岁:优势比(OR) .53, 95%可信区间(95% CI) .28;获得)。与无转移的患者相比,有转移性肿瘤的患者希望有共同的决策(转移:OR 1.61, 95% CI 1.09;2.38)。当比较那些喜欢医生主导决策的患者和那些喜欢控制的患者时,老年患者也更倾向于将控制权交给医生,并且不太倾向于自己做决定:18至40岁vs 75岁:OR .28, 95% CI .15;55)。以中学(8/9年)为参照,拥有高中学历的患者更倾向于患者主导的决策,而不是医生主导的决策(OR 2.00, 95% CI 1.26;3.09)。与背部/脊柱或下肢肉瘤患者相比,腹部/腹膜后肉瘤患者更倾向于在治疗决策中采取控制措施(背部/脊柱:or .18, 95% CI .06;.54,下肢:OR .56, 95% CI .37;.85)。以1250欧元/月的收入为参照,收入越高的患者越有可能控制病情(2750欧元/月:OR为1.7,95% CI为1.0;3.1)。结论:我们的研究结果表明,转移性疾病患者更倾向于寻求联合决策,而年龄越大、受教育程度越低的患者积极参与治疗决策的可能性越小。结果表明,晚期疾病的影响可能会影响参与的偏好。
Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors - Results from the PROSa Study.
Introduction: The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. The objective of this analysis was to identify factors that are associated with sarcoma patients wanting to take a more active or passive role.
Methods: Data was obtained as part of a nationwide multicenter study (PROSa) aiming to investigate the structure and quality of medical care of sarcoma patients in Germany and their determinants. The study was conducted between 2017 and 2020 in 39 study centers. For the present analysis, cross-sectional data of adult patients with sarcoma of any entity were analyzed. Control preference was measured with the control preference scale (CPS). Preferences were divided in patient-led, shared, or physician-led-decision-making. Associated factors were analyzed exploratively using multivariable multinominal logistic regression models. We included socio-economical and medical variables with stepwise backward variable selection.
Results: We included 1081 patients (48.6% female). 402 patients (37.2%) preferred to be in control about treatment decisions, while 400 patients (37.0%) favored shared responsibility. 25.8% (n = 279) wished to rather leave the control to the treating physician. Older patients were more likely to prefer shared decision-making than younger patients aged 18 to 40 years (age group: > 75 years: Odds Ratio (OR) .53, 95% confidence interval (95% CI) .28; .99). Patients with a metastatic tumor desired shared decision making compared to those without metastases (metastasis: OR 1.61, 95% CI 1.09; 2.38). When comparing the patients who preferred physician-led decision making with those who favored to be in control, older patients also preferred leaving the control to the physician and were less inclined to make the decisions by themselves: (18 to > 40 years vs > 75 years: OR .28, 95% CI .15; .55). With secondary school (8/9 years) as reference, patients holding a high school degree were more likely to prefer patient-led decision-making over physician-led decision making (OR 2.00, 95% CI 1.26; 3.09). Patients with sarcoma of the abdomen/retroperitoneum were more predisposed to taking control in treatment decisions compared to those with sarcoma of the back/spine or lower limb (back/spine: OR .18, 95% CI .06; .54, lower limb: OR .56, 95% CI .37; .85). With an income of 1250 €/month as reference, patients with a higher income were more likely to take control (> 2750€/month: OR 1.7, 95% CI 1.0; 3.1).
Conclusion: The findings of our study demonstrate that patients with metastatic disease are more likely to seek a joint decision, while those of higher age and lower education level are less likely to actively participate in treatment decisions. The results suggest that the impact of advanced illness may influence preferences to participate.
期刊介绍:
With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.